Phase II Trial of Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy

Condition:   Squamous Cell Carcinoma of the Esophagus
Interventions:   Drug: Ramucirumab;   Drug: Paclitaxel
Sponsors:   IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest;   Eli Lilly and Company;   Trium Analysis Online GmbH
Not yet recruiting

https://ift.tt/2KTKbbp